Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Type 2 diabetes: a multifaceted disease.

Pearson ER.

Diabetologia. 2019 Jul;62(7):1107-1112. doi: 10.1007/s00125-019-4909-y. Epub 2019 Jun 3. Review.

2.

Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes.

Dujic T, Bego T, Malenica M, Velija-Asimi Z, Ahlqvist E, Groop L, Pearson ER, Causevic A, Semiz S.

Bosn J Basic Med Sci. 2019 May 9. doi: 10.17305/bjbms.2019.4181. [Epub ahead of print]

3.

Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?

Pearson ER.

Clin Pharmacol Ther. 2019 Aug;106(2):329-337. doi: 10.1002/cpt.1484.

PMID:
31012484
4.

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study.

McGovern AP, Dennis JM, Shields BM, Hattersley AT, Pearson ER, Jones AG; MASTERMIND Consortium.

BMC Med. 2019 Apr 12;17(1):79. doi: 10.1186/s12916-019-1307-8.

5.

Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study.

Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, Elders PJM, Rauh SP, Jones AG, Holl RW, Stingl JC, Franks PW, McCarthy MI, 't Hart LM, Pearson ER; IMI DIRECT Consortium.

Diabetes Care. 2019 Jun;42(6):1027-1033. doi: 10.2337/dc18-2182. Epub 2019 Mar 18.

PMID:
30885951
6.

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.

Dennis JM, Henley WE, McGovern AP, Farmer AJ, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, Jones AG; MASTERMIND consortium.

Diabetes Obes Metab. 2019 Jul;21(7):1576-1584. doi: 10.1111/dom.13687. Epub 2019 Apr 4.

7.

Differential Association of Genetic Risk of Coronary Artery Disease With Development of Heart Failure With Reduced Versus Preserved Ejection Fraction.

Mordi IR, Pearson ER, Palmer CNA, Doney ASF, Lang CC.

Circulation. 2019 Feb 12;139(7):986-988. doi: 10.1161/CIRCULATIONAHA.118.038602. No abstract available.

PMID:
30742529
8.

The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.

McGurnaghan SJ, Brierley L, Caparrotta TM, McKeigue PM, Blackbourn LAK, Wild SH, Leese GP, McCrimmon RJ, McKnight JA, Pearson ER, Petrie JR, Sattar N, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group.

Diabetologia. 2019 Apr;62(4):621-632. doi: 10.1007/s00125-018-4806-9. Epub 2019 Jan 10.

PMID:
30631892
9.

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach.

Dennis JM, Shields BM, Jones AG, Pearson ER, Hattersley AT, Henley WE; MASTERMIND consortium.

Clin Epidemiol. 2018 Dec 14;10:1869-1877. doi: 10.2147/CLEP.S179555. eCollection 2018.

10.

Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?

Cordiner RLM, Pearson ER.

Diabetes Obes Metab. 2018 Nov 24. doi: 10.1111/dom.13596. [Epub ahead of print] Review.

PMID:
30471177
11.

Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes.

Patel KA, Weedon MN, Shields BM, Pearson ER, Hattersley AT, McDonald TJ; UNITED study team.

Diabetes Care. 2019 Feb;42(2):e16-e17. doi: 10.2337/dc18-0373. Epub 2018 Nov 8. No abstract available.

PMID:
30409810
12.

A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy.

Grubb AL, McDonald TJ, Rutters F, Donnelly LA, Hattersley AT, Oram RA, Palmer CNA, van der Heijden AA, Carr F, Elders PJM, Weedon MN, Slieker RC, 't Hart LM, Pearson ER, Shields BM, Jones AG.

Diabetes Care. 2019 Feb;42(2):208-214. doi: 10.2337/dc18-0431. Epub 2018 Oct 23.

PMID:
30352895
13.

First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.

Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, Davis A, Hodge KM, Bradfield JP, Zhou K, Guy VC, Åkerlund M, Wod M, Fritsche LG, Vestergaard H, Snyder J, Højlund K, Linneberg A, Käräjämäki A, Brandslund I, Kim CE, Witte D, Sørgjerd EP, Brillon DJ, Pedersen O, Beck-Nielsen H, Grarup N, Pratley RE, Rickels MR, Vella A, Ovalle F, Melander O, Harris RI, Varvel S, Grill VER; Bone Mineral Density in Childhood Study, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Åsvold BO, Yderstræde KB, Pearson ER, Schwartz S, Voight BF, Hansen T, Tuomi T, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2018 Nov;41(11):2396-2403. doi: 10.2337/dc18-1032. Epub 2018 Sep 25.

PMID:
30254083
14.

Pancreatic β-cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes.

Cosentino C, Toivonen S, Diaz Villamil E, Atta M, Ravanat JL, Demine S, Schiavo AA, Pachera N, Deglasse JP, Jonas JC, Balboa D, Otonkoski T, Pearson ER, Marchetti P, Eizirik DL, Cnop M, Igoillo-Esteve M.

Nucleic Acids Res. 2018 Nov 2;46(19):10302-10318. doi: 10.1093/nar/gky839.

15.

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.

Shepherd MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, Hattersley AT, Patel KA; UNITED study.

Diabetologia. 2018 Dec;61(12):2520-2527. doi: 10.1007/s00125-018-4728-6. Epub 2018 Sep 18.

16.

Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.

Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium.

Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2.

17.

Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register.

Read SH, van Diepen M, Colhoun HM, Halbesma N, Lindsay RS, McKnight JA, McAllister DA, Pearson ER, Petrie JR, Philip S, Sattar N, Woodward M, Wild SH; Scottish Diabetes Research Network Epidemiology Group.

Diabetes Care. 2018 Sep;41(9):2010-2018. doi: 10.2337/dc18-0578. Epub 2018 Jul 12.

PMID:
30002197
18.

C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase.

Shields BM, McDonald TJ, Oram R, Hill A, Hudson M, Leete P, Pearson ER, Richardson SJ, Morgan NG, Hattersley AT; TIGI Consortium.

Diabetes Care. 2018 Jul;41(7):1486-1492. doi: 10.2337/dc18-0465. Epub 2018 Jun 7.

19.

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.

Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR; Neonatal Diabetes International Collaborative Group.

Lancet Diabetes Endocrinol. 2018 Aug;6(8):637-646. doi: 10.1016/S2213-8587(18)30106-2. Epub 2018 Jun 4. Erratum in: Lancet Diabetes Endocrinol. 2018 Sep;6(9):e17.

20.

Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.

Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators; ACCORD/ACCORDion Investigators.

Diabetes. 2018 Jul;67(7):1428-1440. doi: 10.2337/db17-1164. Epub 2018 Apr 12.

21.

Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study.

Siddiqui MK, Kennedy G, Carr F, Doney ASF, Pearson ER, Morris AD, Johnson T, McLaughlin MM, Williams RE, Palmer CNA.

Diabetologia. 2018 Jun;61(6):1344-1353. doi: 10.1007/s00125-018-4601-7. Epub 2018 Apr 6.

22.

Pharmacogenetics and target identification in diabetes.

Pearson ER.

Curr Opin Genet Dev. 2018 Jun;50:68-73. doi: 10.1016/j.gde.2018.02.005. Epub 2018 Feb 24. Review.

PMID:
29486427
23.

Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference.

Corbin LJ, Tan VY, Hughes DA, Wade KH, Paul DS, Tansey KE, Butcher F, Dudbridge F, Howson JM, Jallow MW, John C, Kingston N, Lindgren CM, O'Donavan M, O'Rahilly S, Owen MJ, Palmer CNA, Pearson ER, Scott RA, van Heel DA, Whittaker J, Frayling T, Tobin MD, Wain LV, Smith GD, Evans DM, Karpe F, McCarthy MI, Danesh J, Franks PW, Timpson NJ.

Nat Commun. 2018 Feb 19;9(1):711. doi: 10.1038/s41467-018-03109-y. Review.

24.

Pharmacokinetics of metformin in patients with gastrointestinal intolerance.

McCreight LJ, Stage TB, Connelly P, Lonergan M, Nielsen F, Prehn C, Adamski J, Brøsen K, Pearson ER.

Diabetes Obes Metab. 2018 Jul;20(7):1593-1601. doi: 10.1111/dom.13264. Epub 2018 Mar 23.

25.

Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.

Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium.

Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.

26.

Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study.

Gudmundsdottir V, Pedersen HK, Allebrandt KV, Brorsson C, van Leeuwen N, Banasik K, Mahajan A, Groves CJ, van de Bunt M, Dawed AY, Fritsche A, Staiger H, Simonis-Bik AMC, Deelen J, Kramer MHH, Dietrich A, Hübschle T, Willemsen G, Häring HU, de Geus EJC, Boomsma DI, Eekhoff EMW, Ferrer J, McCarthy MI, Pearson ER, Gupta R, Brunak S, 't Hart LM.

PLoS One. 2018 Jan 2;13(1):e0189886. doi: 10.1371/journal.pone.0189886. eCollection 2018.

27.

Rates of glycaemic deterioration in a real-world population with type 2 diabetes.

Donnelly LA, Zhou K, Doney ASF, Jennison C, Franks PW, Pearson ER.

Diabetologia. 2018 Mar;61(3):607-615. doi: 10.1007/s00125-017-4519-5. Epub 2017 Dec 19.

28.

Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS).

Hébert HL, Shepherd B, Milburn K, Veluchamy A, Meng W, Carr F, Donnelly LA, Tavendale R, Leese G, Colhoun HM, Dow E, Morris AD, Doney AS, Lang CC, Pearson ER, Smith BH, Palmer CNA.

Int J Epidemiol. 2018 Apr 1;47(2):380-381j. doi: 10.1093/ije/dyx140. No abstract available.

29.

A common missense variant of LILRB5 is associated with statin intolerance and myalgia.

K Siddiqui M, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, Abelega NU, Carr D, Bloch K, Hallberg P, Yue QY, Pearson ER, Colhoun HM, Morris AD, Dow E, George J, Pirmohamed M, Ridker PM, Doney ASF, Alfirevic A, Wadelius M, Maitland-van der Zee AH, Chasman DI, Palmer CNA; PREDICTION-ADR Consortium.

Eur Heart J. 2017 Dec 21;38(48):3569-3575. doi: 10.1093/eurheartj/ehx467.

30.

Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study.

Molnos S, Wahl S, Haid M, Eekhoff EMW, Pool R, Floegel A, Deelen J, Much D, Prehn C, Breier M, Draisma HH, van Leeuwen N, Simonis-Bik AMC, Jonsson A, Willemsen G, Bernigau W, Wang-Sattler R, Suhre K, Peters A, Thorand B, Herder C, Rathmann W, Roden M, Gieger C, Kramer MHH, van Heemst D, Pedersen HK, Gudmundsdottir V, Schulze MB, Pischon T, de Geus EJC, Boeing H, Boomsma DI, Ziegler AG, Slagboom PE, Hummel S, Beekman M, Grallert H, Brunak S, McCarthy MI, Gupta R, Pearson ER, Adamski J, 't Hart LM.

Diabetologia. 2018 Jan;61(1):117-129. doi: 10.1007/s00125-017-4436-7. Epub 2017 Oct 25.

31.

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.

Eibich P, Green A, Hattersley AT, Jennison C, Lonergan M, Pearson ER, Gray AM.

Diabetes Ther. 2017 Oct;8(5):1031-1045. doi: 10.1007/s13300-017-0296-x. Epub 2017 Sep 6.

32.

Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes.

Dawed AY, Ali A, Zhou K, Pearson ER, Franks PW.

Diabetologia. 2017 Nov;60(11):2231-2239. doi: 10.1007/s00125-017-4404-2. Epub 2017 Aug 25.

33.

The mechanisms of action of metformin.

Rena G, Hardie DG, Pearson ER.

Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3. Review.

34.

Characteristics of people with high visit-to-visit glycaemic variability in Type 2 diabetes.

Noyes JD, Soto-Pedre E, Donnelly LA, Pearson ER.

Diabet Med. 2018 Feb;35(2):262-269. doi: 10.1111/dme.13435. Epub 2017 Aug 17.

35.

Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a Genetics of Diabetes Audit and Research Tayside study (GoDARTS).

Soto-Pedre E, Siddiqui MK, Doney AS, Palmer CNA, Pearson ER, Leese GP.

Pharmacogenet Genomics. 2017 Oct;27(10):356-362. doi: 10.1097/FPC.0000000000000299.

PMID:
28727628
36.

Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.

Shields BM, Shepherd M, Hudson M, McDonald TJ, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson ER, Hattersley AT; UNITED study team.

Diabetes Care. 2017 Aug;40(8):1017-1025. doi: 10.2337/dc17-0224.

37.

Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.

Dujic T, Zhou K, Donnelly LA, Leese G, Palmer CNA, Pearson ER.

Diabetes Obes Metab. 2018 Jan;20(1):211-214. doi: 10.1111/dom.13046. Epub 2017 Aug 25.

38.

A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants.

Wood AR, Jonsson A, Jackson AU, Wang N, van Leewen N, Palmer ND, Kobes S, Deelen J, Boquete-Vilarino L, Paananen J, Stančáková A, Boomsma DI, de Geus EJC, Eekhoff EMW, Fritsche A, Kramer M, Nijpels G, Simonis-Bik A, van Haeften TW, Mahajan A, Boehnke M, Bergman RN, Tuomilehto J, Collins FS, Mohlke KL, Banasik K, Groves CJ, McCarthy MI; Diabetes Research on Patient Stratification (DIRECT), Pearson ER, Natali A, Mari A, Buchanan TA, Taylor KD, Xiang AH, Gjesing AP, Grarup N, Eiberg H, Pedersen O, Chen YD, Laakso M, Norris JM, Smith U, Wagenknecht LE, Baier L, Bowden DW, Hansen T, Walker M, Watanabe RM, 't Hart LM, Hanson RL, Frayling TM.

Diabetes. 2017 Aug;66(8):2296-2309. doi: 10.2337/db16-1452. Epub 2017 May 10.

39.

Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.

Connelly PJ, Lonergan M, Soto-Pedre E, Donnelly L, Zhou K, Pearson ER.

Diabetes Obes Metab. 2017 Nov;19(11):1579-1586. doi: 10.1111/dom.12978. Epub 2017 Jul 5.

40.

Predicting glycated hemoglobin levels in the non-diabetic general population: Development and validation of the DIRECT-DETECT prediction model - a DIRECT study.

Rauh SP, Heymans MW, Koopman AD, Nijpels G, Stehouwer CD, Thorand B, Rathmann W, Meisinger C, Peters A, de Las Heras Gala T, Glümer C, Pedersen O, Cederberg H, Kuusisto J, Laakso M, Pearson ER, Franks PW, Rutters F, Dekker JM.

PLoS One. 2017 Feb 10;12(2):e0171816. doi: 10.1371/journal.pone.0171816. eCollection 2017.

41.

Quantifying the extent to which index event biases influence large genetic association studies.

Yaghootkar H, Bancks MP, Jones SE, McDaid A, Beaumont R, Donnelly L, Wood AR, Campbell A, Tyrrell J, Hocking LJ, Tuke MA, Ruth KS, Pearson ER, Murray A, Freathy RM, Munroe PB, Hayward C, Palmer C, Weedon MN, Pankow JS, Frayling TM, Kutalik Z.

Hum Mol Genet. 2017 Mar 1;26(5):1018-1030. doi: 10.1093/hmg/ddw433.

42.

Statistical power considerations in genotype-based recall randomized controlled trials.

Atabaki-Pasdar N, Ohlsson M, Shungin D, Kurbasic A, Ingelsson E, Pearson ER, Ali A, Franks PW.

Sci Rep. 2016 Nov 25;6:37307. doi: 10.1038/srep37307.

43.

Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.

Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N; DIRECT consortium group.

Diabetes Obes Metab. 2017 Mar;19(3):356-363. doi: 10.1111/dom.12826. Epub 2016 Dec 28.

44.

Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.

Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Hougaard Christensen MM, Out M, Tavendale R, Kubo M, Hedderson MM, van der Heijden AA, Klimčáková L, Pirags V, Kooy A, Brøsen K, Klovins J, Semiz S, Tkáč I, Stricker BH, Palmer C, 't Hart LM, Giacomini KM, Pearson ER.

Clin Pharmacol Ther. 2017 Jun;101(6):763-772. doi: 10.1002/cpt.567. Epub 2017 Feb 3.

45.

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.

Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RHN, Stehouwer CDA, Logie L; MetGen Investigators; DPP Investigators; ACCORD Investigators, Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, Innocenti F, 't Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CNA, Florez JC, Giacomini KM, Pearson ER.

Nat Genet. 2016 Sep;48(9):1055-1059. doi: 10.1038/ng.3632. Epub 2016 Aug 8.

46.

Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study.

Dujic T, Zhou K, Tavendale R, Palmer CN, Pearson ER.

Diabetes Care. 2016 Nov;39(11):1896-1901. Epub 2016 Aug 4.

47.

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD, Lang CC.

Cardiovasc Diabetol. 2016 Jul 15;15:97. doi: 10.1186/s12933-016-0419-0.

48.

Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.

Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, Mallam K, Moudiotis C, Smith R, Fraser B, Robertson S, Greene S, Ellard S, Pearson ER, Hattersley AT; UNITED Team.

Diabetes Care. 2016 Nov;39(11):1879-1888. Epub 2016 Jun 6.

49.

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.

Dawed AY, Donnelly L, Tavendale R, Carr F, Leese G, Palmer CN, Pearson ER, Zhou K.

Diabetes Care. 2016 Nov;39(11):1902-1908. Epub 2016 Jun 6.

PMID:
27271184
50.

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents.

Dawed AY, Zhou K, Pearson ER.

Pharmgenomics Pers Med. 2016 Apr 6;9:17-29. doi: 10.2147/PGPM.S84854. eCollection 2016. Review.

Supplemental Content

Loading ...
Support Center